BiotechTube
Autolus Therapeutics

Autolus Therapeutics

AUTL
London, United Kingdom· Est. 2014

Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.

autolus.com

AUTL · Stock Price

USD 1.320.31 (-19.02%)
Market Cap: $362.0M

Historical price data

AI Company Overview

Autolus Therapeutics is a UK-based, publicly traded company focused on building a fully integrated, next-generation CAR T-cell therapy company. Its mission is to deliver life-changing benefits to patients through advanced autologous T-cell therapies. The company's lead program, obe-cel, is in pivotal development for relapsed/refractory adult ALL and is being explored in additional hematological and solid tumor indications, alongside a preclinical pipeline for autoimmune diseases. Autolus employs its proprietary cell programming, manufacturing, and viral vector technologies to develop precise and controlled therapies.

OncologyAutoimmune Diseases

Technology Platform

Proprietary advanced cell programming platform for designing precise, controlled, and highly active autologous CAR T-cell therapies, integrated with in-house viral vector and semi-automated manufacturing.

Pipeline

13
13 drugs in pipeline
DrugIndicationStageWatch
AUTO CAR T cell therapyPatients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell TherapyPhase 2
Obecabtagene autoleucelLupus NephritisPhase 2
Obecabtagene autoleucelAcute Lymphocytic Leukemia (ALL)Phase 2
Obecabtagene AutoleucelAcute Lymphoblastic LeukemiaPhase 2
AUTO3Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Phase 1/2

Funding History

4
Total raised:$360M
PIPE$100MJul 15, 2020
IPO$150MJun 22, 2018
Series B$80MJul 15, 2017
Series A$30MJun 15, 2015

Opportunities

Major growth opportunities include the potential approval and launch of obe-cel for adult r/r B-ALL, expansion into other B-cell malignancies and solid tumors, and pioneering the application of CAR-T technology in autoimmune diseases, a vast and relatively untapped therapeutic area.

Risk Factors

Key risks include clinical trial failures, regulatory setbacks, challenges in commercializing a complex cell therapy, intense competition in the CAR-T space, and ongoing dependence on raising capital to fund operations.

Competitive Landscape

Autolus competes with large commercial CAR-T leaders (Gilead/Kite, BMS, Novartis) and numerous clinical-stage biotechs. Its differentiation lies in its advanced cell programming focus aimed at improving safety and efficacy, and its early move into autoimmune disease applications.